Encouraging results from a Phase II Trial in patients with AML and ALL

CellCAN is proud to relay this press release from Kiadis Pharma.

Logo Kiadis Pharma 

Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101TM

  • Significant increase in Overall Survival and reduction in Transplant Related Mortality observed in comparison to a historical control group
  • Zero patients developed grade III-IV acute Graft-versus-Host-Disease upon infusion of ATIR101TM
  • Initiation of a randomised Phase III trial in the second half of 2016

Amsterdam, The Netherlands, April 4, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today presents positive results on the primary endpoint of its single dose Phase II trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101TM at the 42nd Annual Meeting of the European Society of Blood and Marrow Transplantation (EBMT) in Valencia, Spain.

The data presented in session O042 by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and the principal investigator for the trial, confirms that ATIR101TM can be safely infused, does not cause grade III-IV Graft-versus-Host-Disease (GVHD) and shows a significant reduction in Transplant Related Mortality (TRM) and a significant improvement in Overall Survival (OS) in comparison to a historical control group of patients undergoing a T-cell depleted haploidentical donor transplantation only.

> Read the entire press release

> View the webcast

Donor lymphocytes depleted of alloreactive T-cells (ATIR101TM) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALL

Leukemia-associated antigen reactive T-cells in ATIR101TM, a recipient-specific allodepleted T-cell product facilitating haploidentical HSCT

Effect of graft source on safety and efficacy in patients undergoing hematopoietic stem cell transplantation

An exploratory, open-label, multicenter study to evaluate safety and efficacy of a two-dose regimen of ATIR101TM in patients with a hematologic malignancy, who received a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor

Connect with a network of Canadian researchers, clinicians, regulatory experts and HQP from coast to coast, through our platforms, workshops and events.

13 NETWORK AFFILIATES. 25 PARTNER ORGANIZATIONS. 181 NETWORK COLLABORATORS.